Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
dMAb AZD5396 · 1 trial · 1 indication
Injection site reactions occurring up to 7 days after administration of the investigational product
Systemic reactions occurring up to 7 days after administration of the investigational product.
SAE will be classified using the CTCAE v5 throughout the study
Visual analogue scale (VAS). A VAS consists of a horizontal line, 10 cm in length, anchored by word descriptors at each end (no pain = 0 cm; worst pain = 10 cm). The VAS score is determined by measuring in centimeters from the left hand end of the line to the point that the patient marks. Absolute initial value and change over time will be described.
Laboratory AEs will be assessed and graded in accordance with the "Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials", issued in September 2007.
The number and percentage of participants in which detection of monoclonal antibody dMAb AZD5396 in serum is achieved will be summarized with a point estimate and corresponding exact 90% Clopper- Pearson confidence interval. These will be summarized per time point within each cohort. We will also estimate the time to 50% decline from peak concentration.
The number and percentage of participants in which detection of monoclonal antibody dMAb AZD8076 in serum is achieved will be summarized with a point estimate and corresponding exact 90% Clopper- Pearson confidence interval. These will be summarized per time point within each cohort. We will also estimate the time to 50% decline from peak concentration.
| Arm | Type | Description |
|---|---|---|
| Cohort A1 - 1x 0.5 mg | EXPERIMENTAL | Participants (n=3) will be administered 0.5 mg of dMAb AZD5396 and 0.5 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0, for a total dose of 0.5 mg of each plasmid. |
| Cohort A2 - 1x 1 mg | EXPERIMENTAL | Participants (n=3) will be administered 1 mg of dMAb AZD5396 and 1 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0, for a total dose of 1 mg of each plasmid. |
| Cohort B - 2x 0.5 mg | EXPERIMENTAL | Participants (n=6) will be administered 0.5 mg of dMAb AZD5396 and 0.5 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3, for a total dose of 1 mg of each plasmid. |
| Cohort C - 2x 1 mg | EXPERIMENTAL | Participants (n=6) will be administered 1mg of dMAb AZD5396 and 1 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3, for a total dose of 2 mg of each plasmid. |
| Cohort D - 2x 0.25 mg | EXPERIMENTAL | Participants (n=6) will be administered 1 mg of dMAb AZD5396 and 1 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3, for a total dose of 2 mg of each plasmid. |
| Cohort E - 2x 2 mg | EXPERIMENTAL | Participants (n=5) will be administered 2 mg of dMAb AZD5396 and 2 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0 and D3, for a total dose of 4 mg of each plasmid. |
| Cohort F - 2x 0.5 mg | EXPERIMENTAL | Participants (n=5) will be administered 0.5 mg of dMAb AZD5396 and 0.5 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0070 parameter on D0 and D3, for a total dose of 1 mg of each plasmid. |
| Cohort G - 4x 0.5 mg | EXPERIMENTAL | Participants (n=5) will be administered 0.5 mg of dMAb AZD5396 and 0.5 mg of dMAb AZD8076 with Hylenex® delivered intramuscularly using the side port needle followed by electroporation (EP) with OpBlock 0078 parameter on D0, D3, D28 and D31, for a total dose of 2 mg of each plasmid. |
| Name | Type | Description |
|---|---|---|
| dMAb AZD5396 | COMBINATION_PRODUCT | Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP. |
| dMAb AZD8076 | COMBINATION_PRODUCT | Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP. |
| CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device | COMBINATION_PRODUCT | The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076. |
| Hylenex | DRUG | Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site. |
| CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device | COMBINATION_PRODUCT | The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076. |
Inclusion Criteria 1. Age 18-60 years. 2. Able to provide consent to participate and having signed an Informed Consent Form (ICF). 3. Able and willing to comply with all study procedures. 4. Body mass index (BMI) between 20 and 31, inclusive. 5. Screening laboratory must be within normal limits or ...
dMAb AZD5396 is an investigational monoclonal antibody developed by Inovio Pharmaceuticals, Inc. It was studied in a Phase 1 clinical trial titled dMAbs for Prevention of COVID-19, which enrolled 61 healthy adult volunteers in the United States. The trial has been completed.
dMAb AZD5396 was evaluated for the prevention of COVID-19. Its only recorded clinical trial, NCT05293249, was conducted in healthy volunteers rather than in patients with an active infection, reflecting a preventive or prophylactic use. The specific disease indications for the asset are not publicly disclosed.
dMAb AZD5396 is being developed by Inovio Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker INO. Inovio is the sponsor associated with the asset's clinical program.
dMAb AZD5396 is in Phase 1 development. It is an investigational monoclonal antibody and has not been approved by the FDA. Its single Phase 1 trial, NCT05293249, has been completed, and no active trials are currently listed for the asset.
dMAb AZD5396 has been studied in one clinical trial, NCT05293249, titled dMAbs for Prevention of COVID-19. That Phase 1 trial enrolled 61 healthy volunteers aged 18 and older in the United States and has been completed. It used a controlled design without randomization or double blinding.
Yes. dMAb AZD5396 is a monoclonal antibody, a type of engineered antibody therapy. It belongs to the -mab antibody class and was developed as an investigational biologic rather than a small molecule drug.